onr:"swepub:oai:DiVA.org:uu-81295"
Search: onr:"swepub:oai:DiVA.org:uu-81295" > Phase II study of c...
- 1 of 1
- Previous record
- Next record
- To hitlist
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
- Batista, N (author)
- Perez-Manga, G (author)
- Constenla, M (author)
- show more...
- Ruiz, A (author)
- Carabantes, F (author)
- Castellanos, J (author)
- Gonzalez Baron, M (author)
- Villman, K (author)
- Söderberg, M (author)
- Casinello, J (author)
- Regueiro, P (author)
- Murias, A (author)
- show less...
- (creator_code:org_t)
- 2004
- 2004
- English.
- In: Br J Cancer. - 0007-0920. ; 90:9, s. 1740-6
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral capecitabine (1000 mg m(-2) twice daily, days 1-14) plus i.v. paclitaxel (175 mg m(-2), day 1) in anthracycline-pretreated advanced/MBC. In all, 73 patients were enrolled at 13 Swedish and Spanish centres. The objective response rate was 52% (95% confidence interval (CI): 40-63%) in the intent-to-treat population, including complete responses in 11%. Disease was stabilised in a further 29%. The median time to disease progression (TTP) was 8.1 months and the median overall survival was 16.5 months. The combination was generally well tolerated with a predictable safety profile. The most common treatment-related nonhaematological adverse events were hand-foot syndrome (42%), alopecia (30%) and diarrhoea (26%). The only treatment-related Grade 3/4 adverse events occurring in >5% of patients were alopecia (22%) and hand-foot syndrome (11%). Grade 3/4 neutropenia and lymphocytopenia were reported in 12 and 14% of patients, respectively. Capecitabine plus paclitaxel is highly active with a favourable safety profile in anthracycline-pretreated MBC.
Keyword
- Adolescent
- Adult
- Aged
- Anthracyclines/therapeutic use
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
- Breast Neoplasms/*drug therapy/mortality
- Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives
- Disease Progression
- Female
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Paclitaxel/administration & dosage/adverse effects
- Survival Rate
- Treatment Outcome
Publication and Content Type
- ref (subject category)
- art (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Batista, N
- Perez-Manga, G
- Constenla, M
- Ruiz, A
- Carabantes, F
- Castellanos, J
- show more...
- Gonzalez Baron, ...
- Villman, K
- Söderberg, M
- Ahlgren, J
- Casinello, J
- Regueiro, P
- Murias, A
- show less...
- Articles in the publication
- Br J Cancer
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
